N-Dodecanoyl-NBD-D-erythro-dihydrosphingosineN-Dodecanoyl-NBD-D-erythro-dihydrosphingosine
Move your mouse over image or click to enlarge

N-Dodecanoyl-NBD-D-erythro-dihydrosphingosine

N-C12:0-NBD-Dihydroceramide; N-C12:0-NBD-D-erythro-Dihydrosphingosine

This high purity fluorescent product is ideal for the identification of dihydroceramide in samples and biological systems. 7- nitrobenzofurazan (NBD) has been shown to have only a small influence on lipid adsorption into cells and cellular membranes. This fluorescent analog of natural dihydroceramide is comparable to C12:0-dyhidroceramide in many biological functions.1,2 Dihydroceramide is a critical intermediate in the synthesis of many complex sphingoid bases. Inhibition of dihydroceramide synthesis by some fungal toxins that have a similar structure causes an increase in dihydroceramide and dihydroceramide-1-phosphate and a decrease in other sphingolipids leading to a number of diseases including oesophageal cancer. Dihydroceramide, synthesized by the acylation of sphinganine, is subsequently converted into ceramide via a desaturase enzyme. N-(4-Hydroxyphenyl) retinamide (4-HPR) has been tested as an anti-cancer agent. It inhibits the dihydroceramide desaturase enzyme in cells resulting in a high concentration of dihydroceramide and dihydro-sphingolipids and this is thought to be the cause of the anti-cancer effects.3 Dihydrosphingosine induces cell death in a number of types of malignant cells.
Cat# Size Price Qty Buy
1625 100 ug £187.50

Additional Information

Property Value or Rating
Product Size 100 ug
Manufacturer Matreya, LLC
Empirical Formula C36H63N5O6
CAS# 474943-05-0
Formula Weight 661.9
Source synthetic
Purity 98+%
Analytical Methods TLC
Natural Source Synthetic
Solubility methanol, chloroform/methanol, 2:1
Physical Appearance A neat solid
Storage -20°C
References

1. J. Kok et al. “Dihydroceramide Biology STRUCTURE-SPECIFIC METABOLISM AND INTRACELLULAR LOCALIZATION” Journal of Biological Chemistry, Vol. 272 pp. 21128-21136, 1997 
2. J. Hsu et al. “Enhanced endothelial delivery and biochemical effects of -galactosidase by ICAM-1-targeted nanocarriers for Fabry disease” Journal of Controlled Release, doi:10.1016/j.jconrel.2010.10.031, 2010 
3. W. Zheng “Fenretinide increases dihydroceramide and dihydrosphingolipids due to inhibition of dihydroceramide desaturase” Georgia Institute of Technology, 2006

Related Documents